Adverse Events Definition Should Be Narrower, IRB Groups Tell FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The Consortium of Independent Review Boards favors reporting only adverse events that "probably or definitely" related to the study drug. Current regulation requires adverse events to be reported to IRBs if they are "at least possibly" related to the drug.
You may also be interested in...
Phase III Trial Oversight Should Rely On Adverse Event "Summaries," CRO Association Says
The Association of Clinical Research Organizations supports using partially blinded data summaries to help institutional review boards overseeing multi-center trials
Phase III Trial Oversight Should Rely On Adverse Event "Summaries," CRO Association Says
The Association of Clinical Research Organizations supports using partially blinded data summaries to help institutional review boards overseeing multi-center trials
Clinical Trial Adverse Event Reporting To Be Discussed At FDA Public Hearing
Agency announces March 21 hearing to consider the types of adverse event reports that should be submitted to institutional review boards. The proliferation of multi-center studies is one reason behind FDA’s decision to revisit the process by which IRBs assess such information.